Abstract: The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

Abstract: Novel neoantigen-eliciting antibody drug conjugates are disclosed. These compounds or pharmaceutically acceptable salts, hydrates, solvates, isomers, or tautomers thereof are useful for the treatment of disorders, including but not limited to pancreatic cancer and other check point positive cancers. More particularly, these compounds may comprise biologically active polypeptides or hormones modified to include the attachment of therapeutic compounds using linkers. The compounds of the disclosure, or pharmaceutically acceptable salts, hydrates, solvates, isomers, or tautomers thereof, also comprise therapeutic compounds connected to linkers.

Abstract: Disclosed is a computer-implemented method for analyzing server for security vulnerabilities. The method includes selecting a first server from a plurality of servers, wherein the first sever includes a plurality of accounts. The method includes identifying, by a password vulnerability scanner, weak accounts in the plurality of accounts including a first weak account. The method includes determining, by a user risk engine, a user risk score for a user associated with the weak account. The method includes determining, by a server risk engine, a server risk score for the first server, wherein the server risk score is based on a set of server factors and a set of data factors. The method includes generating, by a smart risk scorer, an overall risk score for the first server. The method includes categorizing, based on the overall risk score of the first sever, a risk level for the first server.

Abstract: The present disclosure features useful methods to treat an ALT-positive cancer and/or a cancer having a deficiency in ATRX and/or DAXX, e.g., in a subject in need thereof. In some embodiments, the methods described herein are useful in the treatment of cancer in combination with anti-cancer therapies.

Abstract: Novel insulin, insulin-fusion proteins and insulin homologs protein-small molecule drug conjugates, where conjugation takes place through the use of cleavable and non-cleavable linkers are disclosed. The small molecules chemically linked to the protein carrier are imported into the specific insulin-responsive target tissue or cell through receptor-mediated endocytosis and released from the carrier protein through enzymatic cleavage of the linker-drug moiety or through lysosomal degradation of the carrier protein. Free drug can then act to modify insulin receptor-triggered biochemical pathways that are altered in conditions of insulin-resistance. Drug will correct altered pathway allowing re-sensitization of receptor signaling. This will greatly aid in the resolution of pathologies either initiated at the onset of insulin resistance or exacerbated by it.

Abstract: Novel leptin and leptin-fusion protein-small molecule drug conjugates are disclosed, where conjugation takes place through the use of cleavable and non-cleavable linkers. The small molecules chemically linked to the protein carrier are imported into the specific leptin-responsive target tissue or cell through receptor-mediated endocytosis and released from the carrier protein through enzymatic cleavage of the linker-drug moiety or through lysosomal degradation of the carrier protein. Free drug then act to modify leptin receptor-triggered biochemical pathways that are altered in conditions of leptin-resistance. Drug will correct altered pathway allowing resensitization of receptor signaling. This can greatly aid in the resolution of pathologies either initiated at the onset of leptin resistance or exacerbated by it.

Abstract: The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

Abstract: The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

Abstract: Disclosed is a computer-implemented method for analyzing server for security vulnerabilities. The method includes selecting a first server from a plurality of servers, wherein the first sever includes a plurality of accounts. The method includes identifying, by a password vulnerability scanner, weak accounts in the plurality of accounts including a first weak account. The method includes determining, by a user risk engine, a user risk score for a user associated with the weak account. The method includes determining, by a server risk engine, a server risk score for the first server, wherein the server risk score is based on a set of server factors and a set of data factors. The method includes generating, by a smart risk scorer, an overall risk score for the first server. The method includes categorizing, based on the overall risk score of the first sever, a risk level for the first server.

Abstract: The present disclosure features useful methods to treat cancer having a deficiency in ARID1 A and/or mismatch repair deficiency, e.g., in a subject in need thereof. In some embodiments, the methods described herein are useful in the treatment of cancer in combination with immunotherapies.

Abstract: The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

Abstract: An active ubiquitin E3 ligase, GRAIL, is crucial in the induction of anergy in cells of the immune system, and in the regulation of cellular proliferation. GRAIL is shown to associate with, and be regulated by Otubain isoforms, including OTUBAIN-1 (DOG, the Destabilizer of GRAIL) and an alternative reading frame splice variant of OTUBAIN-1 (SOG, the Stabilizer of GRAIL). These proteins play opposing roles in the regulation of GRAIL auto-ubiquitination and consequently on its ability to induce anergy and regulate cellular proliferation. DOG serves as an adaptor protein, recruiting the DUB USP8. One major substrate for USP8 is the Ras exchange factor Ras-GRF1, and this protein can be found in a complex with USP8 and GRAIL, which complex is ubiquitinated by GRAIL.

Abstract: An active ubiquitin E3 ligase, GRAIL, is crucial in the induction of anergy in cells of the immune system, and in the regulation of cellular proliferation. GRAIL is shown to associate with, and be regulated by Otubain isoforms, including OTUBAIN-1 (DOG, the Destabilizer of GRAIL) and an alternative reading frame splice variant of OTUBAIN-1 (SOG, the Stabilizer of GRAIL). These proteins play opposing roles in the regulation of GRAIL auto-ubiquitination and consequently on its ability to induce anergy and regulate cellular proliferation. DOG serves as an adaptor protein, recruiting the DUB USP8. One major substrate for USP8 is the Ras exchange factor Ras-GRF1, and this protein can be found in a complex with USP8 and GRAIL, which complex is ubiquitinated by GRAIL.